• 500-patient study confirms clinical utility of hTERT testing as an adjunct to urine cytology
• Study results were presented by Johns Hopkins at USCAP meeting in Vancouver
Melbourne, Australia, 22 March 2018: Sienna Cancer Diagnostics Ltd (ASX:SDX), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce that renowned research institute, Johns Hopkins University School of Medicine, has today presented the results of its study using Sienna’s in-vitro diagnostic (IVD) hTERT test at the United States and Canadian Academy of Pathology (USCAP) 2018 Annual Meeting.
For further information please download PDF attached:
Download this document
